[SCHEDULE 13G/A] Sunshine Biopharma Inc. Amended Passive Investment Disclosure
Sunshine Biopharma holders report 9.99% stake
Sunshine Biopharma Inc. received an updated Schedule 13G/A from Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting their beneficial ownership in the company’s common stock.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Sunshine Biopharma Inc. received an updated Schedule 13G/A from Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting their beneficial ownership in the company’s common stock. As of June 30, 2026, they may be deemed to beneficially own 235,697 shares of common stock issuable upon exercise of a warrant, representing 9.99% of the outstanding common stock. This percentage is calculated using 2,123,635 shares outstanding as of May 28, 2026 plus the 235,697 warrant shares. Additional warrant shares are contractually blocked from exercise above ownership caps of 9.99% for one warrant and 4.99% for another, which limits the reportable beneficial ownership.
Key Figures
Beneficially owned shares:235,697 sharesPercent of class:9.99%Shares outstanding baseline:2,123,635 shares+3 more
6 metrics
Beneficially owned shares235,697 sharesShares of common stock issuable upon exercise of Intracoastal Warrant 1
Percent of class9.99%Beneficial ownership percentage of Sunshine Biopharma common stock
Shares outstanding baseline2,123,635 sharesCommon stock outstanding as of May 28, 2026 used in ownership calculation
Additional Warrant 1 shares excluded1,861,624 sharesShares from Intracoastal Warrant 1 excluded due to 9.99% blocker provision
Additional Warrant 2 shares excluded100,000 sharesShares from Intracoastal Warrant 2 excluded due to 4.99% blocker provision
Total potential shares without blockers2,197,321 sharesPotential beneficial ownership if blocker provisions did not apply
Key Terms
beneficial ownership, blocker provision, warrant, CUSIP No., +1 more
5 terms
beneficial ownershipfinancial
"each of the Reporting Persons may have been deemed to have beneficial ownership of 235,697 shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
blocker provisionfinancial
"Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise"
warrantfinancial
"shares of Common Stock issuable upon exercise of a warrant held by Intracoastal"
A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.
CUSIP No.financial
"CUSIP No.: 867781809"
limited liability companyfinancial
"Intracoastal Capital LLC, a Delaware limited liability company"
A limited liability company (LLC) is a business structure that separates the owners’ personal assets from the company’s debts and legal obligations, like a protective shield that keeps personal savings and property distinct from business risk. For investors, that protection reduces personal financial exposure and often brings flexible rules for profit sharing and taxes, but it can also affect how easily interests are bought or sold and how decisions are made.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Sunshine Biopharma (SBFM) do the reporting persons disclose?
The reporting persons disclose beneficial ownership of 235,697 shares of Sunshine Biopharma common stock, representing 9.99% of the class, based on 2,123,635 shares outstanding plus the warrant shares included in the calculation.
Who are the reporting persons on this Sunshine Biopharma (SBFM) Schedule 13G/A?
The Schedule 13G/A is filed jointly by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. Kopin and Asher are individuals in the United States, and Intracoastal is a Delaware limited liability company.
How is the 9.99% beneficial ownership in SBFM calculated?
The 9.99% beneficial ownership is based on 2,123,635 Sunshine Biopharma shares outstanding as of May 28, 2026, plus 235,697 shares of common stock issuable upon exercise of a warrant held by Intracoastal included in the ownership.
What blocker provisions limit the reporting persons’ ownership in Sunshine Biopharma (SBFM)?
One Intracoastal warrant has a 9.99% blocker, and a second warrant has a 4.99% blocker. These provisions prevent exercises that would push beneficial ownership above those percentages, so excluded shares are not counted in the reported position.
How many additional SBFM shares are tied to the Intracoastal warrants but excluded by blockers?
The filing notes 1,861,624 additional shares from Intracoastal Warrant 1 and 100,000 from Intracoastal Warrant 2 are excluded due to blocker provisions, even though they are issuable upon exercise of those warrants.
What would the reporting persons’ SBFM beneficial ownership be without blocker provisions?
Without the blocker provisions, the reporting persons may have been deemed to beneficially own 2,197,321 shares of Sunshine Biopharma common stock, reflecting all shares issuable under the referenced Intracoastal warrants.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Sunshine Biopharma Inc.
(Name of Issuer)
Common stock, par value $0.001 per share
(Title of Class of Securities)
867781809
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
867781809
1
Names of Reporting Persons
Mitchell P. Kopin
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
235,697.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
235,697.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
235,697.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
867781809
1
Names of Reporting Persons
Daniel B. Asher
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
235,697.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
235,697.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
235,697.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
867781809
1
Names of Reporting Persons
Intracoastal Capital LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
235,697.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
235,697.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
235,697.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Sunshine Biopharma Inc.
(b)
Address of issuer's principal executive offices:
333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301
Item 2.
(a)
Name of person filing:
This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)
Address or principal business office or, if none, residence:
The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)
Citizenship:
Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)
Title of class of securities:
Common stock, par value $0.001 per share
(e)
CUSIP No.:
867781809
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of the close of business on June 30, 2026, each of the Reporting Persons may have been deemed to have beneficial ownership of 235,697 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 1"), and all such shares of Common Stock represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 2,123,635 shares of Common Stock outstanding as of May 28, 2026, as reported by the Issuer, plus (2) 235,697 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 1,861,624 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock and (II) 100,000 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 2,197,321 shares of Common Stock.
(b)
Percent of class:
9.99%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
235,697
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
235,697
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
